Sangon Biotech
Leading provider of life science tools and services in China, offering products in DNA synthesis, R&D reagents, genetic sequencing, and protein-related products. Serves over 7,000 academic institutions and 40,000 biotech companies.
Notes
Sangon Biotech is one of China's leading providers of life science tools and services. Founded in 2001 and headquartered in Shanghai, the company has grown to serve a vast customer base including over 7,000 academic institutions and 40,000 biotech companies across China.
The company offers a comprehensive range of products and services including:
- DNA/RNA synthesis and oligo manufacturing
- R&D reagents and consumables
- Genetic sequencing services
- Protein-related products and services
- Custom biology services
In August 2023, Sangon Biotech raised $290 million in strategic financing, with Novo Holdings participating as an investor, highlighting the company's strong position in the Chinese life sciences market.
Team
- Leadership team operates primarily in Chinese market
Additional Research Findings
- Raised $290 million strategic financing (August 2023)
- Novo Holdings participated in funding
- DNA synthesis, R&D reagents, genetic sequencing services
- Life science tools and services provider
- Serves 7,000+ academic institutions and 40,000+ biotech companies
- Shanghai, China headquarters
- Founded in 2001
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Novo Holdings | Hellerup, Denmark | biotech-focused | seedseries-a+3 | 13 |